semaglutide vs tirzepatide cardiovascular versus Once Weekly in Patients with Type 2 Diabetes Tirzepatide vs. Semaglutide: Which Weight

The medication itself contains the same active compound, but compounded formulations are prepared by individual pharmacies rather than manufactured by Eli Lilly under FDA oversight

Elrod, J

Data from the SURPASS-PEDS trials, which was simultaneously published in The Lancet , showed once-weekly subcutaneous tirzepatide (Mounjaro, Eli Lilly), a GIP/GLP-1 dual agonist, conferred significant reductions in both HbA1c and BMI at 30 weeks compared with placebo

However, it is crucial to ensure that you obtain your medication from a source

A 2023 study on tirzepatide found that participants who switched to a placebo after losing about 21% of their body weight in three years gained back about 14% over another year

Usually minor and temporary